These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma. Gött H; Uhl E Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806 [TBL] [Abstract][Full Text] [Related]
5. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060 [TBL] [Abstract][Full Text] [Related]
6. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features. Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058 [TBL] [Abstract][Full Text] [Related]
13. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma. Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537 [TBL] [Abstract][Full Text] [Related]
14. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477 [TBL] [Abstract][Full Text] [Related]
15. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples. Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669 [TBL] [Abstract][Full Text] [Related]
16. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413 [TBL] [Abstract][Full Text] [Related]